Biomica plans to use the $20 million in new funding from Shanghai Healthcare Capital to further develop its pipeline of microbiome-based therapeutics.
New Funding Round for Microbiome-Based Therapeutics
This entry was posted in AI, Big Data Analytics, healthcare and tagged Biomica, Evogene, Forbes Gil Press. Bookmark the permalink.